HTA Strategy Conference 2026: Stop Attending Networking Events and Start Solving Market Access Problems

2026-06-23T00:06:03Z

Joseph-torres12: Created page with "<html><p> I have spent 11 years in pharma commercial operations and managed markets. If I had a dollar for every time someone told me a conference offered “unparalleled networking,” I would have retired a decade ago. Here is the reality: most conferences are just expensive happy hours where you talk to people who have the same job title you do, at a different company, chasing the same formulary placement you are.</p> <p> If you are looking for an <strong> HTA strateg..."

<html><p> I have spent 11 years in pharma commercial operations and managed markets. If I had a dollar for every time someone told me a conference offered “unparalleled networking,” I would have retired a decade ago. Here is the reality: most conferences are just expensive happy hours where you talk to people who have the same job title you do, at a different company, chasing the same formulary placement you are.</p> <p> If you are looking for an <strong> HTA strategy conference 2026</strong>, stop looking for "networking." Start looking for data. You need to be in rooms where the people holding the pen on P&T decisions, oncology pathways, and health system budgets are actually speaking. If you cannot look at an attendee list and identify three people who can kill your product's launch, you are wasting your travel budget.</p> <p> After a decade of planning these, I’ve learned to track "who I actually meet" in a running spreadsheet. Most events get a one-star rating because the "who" is just a sea of sales directors looking for prescriber reach, not access strategy. Here is how to pick your 2026 calendar.</p> <h2> The HTA Strategy Landscape: Payer vs. Health System</h2> <p> There is a massive divide between "payer marketing" and "HTA strategy." Payer marketing is about value props and sliding decks. HTA strategy is about evidence generation, reimbursement economics, and navigating the increasingly complex web of health system formulary execution. If your strategy focuses on prescriber reach alone, you are dead on arrival.</p> <p> In 2026, the pressure on pricing and affordability is not just coming from national payers; it is coming from Integrated Delivery Networks (IDNs) and cancer centers that are tired of being the ones who have to explain why a therapy costs $300,000 to their board. If you want to understand how your drug fits, you need to hear how the gatekeepers at the health system level view your data.</p> <h3> Conference Comparison Table for 2026 Planning</h3> Conference Primary Attendee HTA Value Best For AMCP Managed Care Pharmacists / P&T Staff High (Formulary mechanics) Understanding PBM/Plan hurdles The Health Management Academy (THMA) Health System Executives Extreme (Budget/Adoption) C-Suite strategy alignment ACCC Oncology Administrators / Clinicians High (Real-world access) Oncology pathway operationalization <h2> AMCP: The Engine Room of P&T Decisions</h2> <p> The <strong> Academy of Managed Care Pharmacy (AMCP)</strong> is not about high-level strategy; it is about the mechanics of the formulary. When you go here, you aren't looking for "synergy"—use that word and I will find you and ask you to define it. You are looking for the people who manage the evidence dossiers.</p> <p> In 2026, your <strong> pricing and access summit</strong> strategy should focus on AMCP to understand how your <strong> evidence generation and reimbursement</strong> data is actually digested. Do not just attend the sessions. Find the pharmacist who is responsible for the clinical review of your therapeutic class. Ask them: "What was the single piece of evidence that made you pause before approving this on the formulary?"</p> <h2> The Health Management Academy (THMA): The C-Suite Reality</h2> <p> If you want to understand health system adoption, <strong> The Health Management Academy (THMA)</strong> is where you find the people who actually authorize the capital spend. This isn't where you find the junior access manager; this is where you find the people who define the health system's financial viability.</p> <p> Pricing and affordability aren't just numbers on a spreadsheet to them; they are institutional risks. If you are presenting HTA data here, your messaging must shift from "clinical efficacy" to "institutional stability." If you can’t explain how your drug improves the financial health of the system—not just the patient—you will be ignored.</p> <h2> ACCC: Bridging the Gap in Oncology</h2> <p> The <strong> Association of Cancer Care Centers (ACCC)</strong> is critical if your product touches oncology. It is the bridge between the high-level HTA strategy and the reality of the infusion suite. Many pharma companies spend millions on market access strategies that fall apart because they didn't account for the administrative burden of chemotherapy reimbursement in a private practice versus a hospital-owned clinic.</p><p> <iframe src="https://www.youtube.com/embed/K-DO-iDdTsc" width="560" height="315" style="border: none;" allowfullscreen="" ></iframe></p><p> <img src="https://images.pexels.com/photos/4174740/pexels-photo-4174740.jpeg?auto=compress&cs=tinysrgb&h=650&w=940" style="max-width:500px;height:auto;" ></img></p> <p> ACCC allows you to talk to the directors who handle the day-to-day reimbursement battles. If your HTA strategy relies on a digital tool for reimbursement, test that tool against the real-world workflow here. If your "digital evidence" is just a PDF hidden behind a <strong> Cookie Law Info plugin</strong> on your website—and yes, I’ve seen enough UI scrapes to know that's how most of you present your data—you need a wake-up call. Nobody in a busy clinic is clicking through your GDPR/cookie banners to find your clinical evidence. They want a button that works, or they want a human who can get them paid.</p> <h2> Digital Tools and the "Monday Morning" Problem</h2> <p> Every conference I attend, I ask myself: "What would I do differently on Monday?" If the answer is "nothing," the conference failed. Most of you collect business cards and never send an email. </p> <p> We are seeing an influx of digital tools in evidence generation and reimbursement. If you are presenting these at a conference, stop focusing on the "sleek interface." Focus on the integration. Does your tool plug into their EMR? Does it reduce the time a nurse spends on a prior authorization? If your digital strategy is just a flashy UI, you’re missing the point of the 2026 market access landscape.</p> <p> Look at your company’s digital footprint. When you scrape your own site, do you see a mess of cookie pop-ups and broken links, or do you see a clear path to the data a payer needs? If your site-level UX (like the standard UI elements seen in many site-wide cookie compliance plugins) is cluttered, your HTA data is probably buried, too.</p> <h2> Actionable Steps for Your 2026 HTA Strategy</h2> <ol> <li> <strong> Perform a "Who is Actually There" Audit:</strong> Stop relying on conference marketing materials. Reach out to the organizers and ask for the list of *previous* attendees by title, not by company. If it's all marketing VPs, go elsewhere.</li> <li> <strong> Kill the Buzzwords:</strong> If your team uses words like "streamline" or "integrated solution," force them to explain the *process* in three sentences. If they can't, your HTA strategy is likely just marketing fluff.</li> <li> <strong> Map Your Evidence to the Payer's Headache:</strong> Your clinical data is useless if it doesn't solve a budget issue. Use the conference to test which budget issue (e.g., patient assistance, pharmacy spend, infusion cost) is the current priority.</li> <li> <strong> Monday Morning Audit:</strong> Before you leave the conference, write down one specific piece of intelligence you gathered about a specific stakeholder's pain point. If you don't have that by lunch on Wednesday, you are at the wrong conference.</li> </ol> <h2> The Bottom Line</h2> <p> Most conferences are designed to keep you comfortable. You want a conference that keeps you uncomfortable. You want to be at an event where your product's value proposition is scrutinized by the people who have to pay for it. Whether you are at AMCP, THMA, or ACCC, remember: your https://pharmashots.com/33979/pharma-market-access-conferences-2026/ job is not to sell; your job is to understand why someone else would choose to say "no" to your product, and then provide the data to make that answer "yes."</p> <p> If you aren't walking away with a list of "things I need to fix by Monday," you aren't doing the work. Stop chasing the networking, start chasing the insight.</p><p> <img src="https://images.pexels.com/photos/11074302/pexels-photo-11074302.jpeg?auto=compress&cs=tinysrgb&h=650&w=940" style="max-width:500px;height:auto;" ></img></p></html>

Qqpipi.com - User contributions [en]

HTA Strategy Conference 2026: Stop Attending Networking Events and Start Solving Market Access Problems